# Phase I Study of S64315 Administred Intravenously in Patients With Acute Myeloid Leukaemia or Myelodysplastic Syndrome

> **NCT02979366** · PHASE1 · COMPLETED · sponsor: **Institut de Recherches Internationales Servier** · enrollment: 38 (actual)

## Conditions studied

- Acute Myeloid Leukaemia (AML)
- Myelodysplastic Syndrome (MDS)

## Interventions

- **DRUG:** S64315 once a week
- **DRUG:** S64315 twice a week

## Key facts

- **NCT ID:** NCT02979366
- **Lead sponsor:** Institut de Recherches Internationales Servier
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-03-15
- **Primary completion:** 2020-05-11
- **Final completion:** 2020-05-11
- **Target enrollment:** 38 (ACTUAL)
- **Last updated:** 2022-05-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02979366

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02979366, "Phase I Study of S64315 Administred Intravenously in Patients With Acute Myeloid Leukaemia or Myelodysplastic Syndrome". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02979366. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*